Gravier Pierre 4
4 · PTC THERAPEUTICS, INC. · Filed Jul 16, 2026
Research Summary
AI-generated summary of this filing
PTC Therapeutics CFO Pierre Gravier Sells 3,494 Shares
What Happened
Pierre Gravier, Chief Financial Officer of PTC Therapeutics (PTCT), disposed of 3,494 shares on July 14, 2026 at $80.35 per share, generating proceeds of approximately $280,743. The sale was made pursuant to an irrevocable sell-to-cover election to satisfy tax withholding upon the vesting of restricted stock units (RSUs).
Key Details
- Transaction date and price: July 14, 2026 — 3,494 shares sold at $80.35 each.
- Total proceeds: ~ $280,743.
- Reason / footnote: The sale was an automatic sell-to-cover to satisfy withholding obligations related to the vesting of 6,500 RSUs from a July 13, 2023 grant (footnote F1).
- Additional disclosure: Filing notes inclusion of 162 shares acquired under the issuer’s employee stock purchase plan for the period ended June 30, 2026 (footnote F2).
- Shares owned after transaction: Not specified in the Form 4 filing.
- Filing timeliness: Report filed July 16, 2026 (within the SEC’s typical two-business-day Form 4 reporting window).
Context
Sell-to-cover transactions are routine tax-related disposals triggered when RSUs vest and do not necessarily indicate the insider’s view of the company. This was a sale to meet withholding obligations rather than an open-market sell motivated by diversification or liquidity needs (the filing does not state motivation).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-07-14$80.35/sh−3,494$280,743→ 83,986 total
Footnotes (2)
- [F1]Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs
- [F2]Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.